

Phospho-C-Cbl-Y770 Antibody
Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AE1007b**Specification**

Phospho-C-Cbl-Y770 Antibody - Product Information

Application	WB, IHC, IF
Primary Accession	P22681
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Concentration	1mg/ml
Isotype	Rabbit IgG
Calculated MW	99633

Phospho-C-Cbl-Y770 Antibody - Additional Information**Gene ID** 867**Other Names**

E3 ubiquitin-protein ligase CBL, 632-, Casitas B-lineage lymphoma proto-oncogene, Proto-oncogene c-Cbl, RING finger protein 55, Signal transduction protein CBL, CBL, CBL2, RNF55

Target/Specificity

The antibody was affinity-purified from rabbit antiserum using epitope-specific phosphopeptide column, and the antibody against non-phosphopeptide was removed using non-phosphopeptide column corresponding to the phosphorylation site.

Dilution

WB~~1:500~1000

IHC~~1:50~1:100

IF~~1:100~200

Format

affinity Purified IgG, in PBS, 0.02% sodium azide and 50% glycerol.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Phospho-C-Cbl-Y770 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Phospho-C-Cbl-Y770 Antibody - Protein Information**Name** CBL

Synonyms CBL2, RNF55

Function

E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors (PubMed:10514377, PubMed:11896602, PubMed:14661060, PubMed:14739300, PubMed:15190072, PubMed:17509076, PubMed:18374639, PubMed:19689429, PubMed:21596750, PubMed:28381567). Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome (PubMed:10514377, PubMed:14661060, PubMed:14739300, PubMed:17094949, PubMed:17509076, PubMed:17974561). Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR and mediates their ubiquitination to terminate signaling (PubMed:15190072, PubMed:18374639, PubMed:21596750). Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation (PubMed:11896602). Ubiquitinates EGFR and SPRY2 (PubMed:17094949, PubMed:17974561). Ubiquitinates NECTIN1 following association between NECTIN1 and herpes simplex virus 1/HHV-1 envelope glycoprotein D, leading to NECTIN1 removal from cell surface (PubMed:28381567). Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis (PubMed:15190072, PubMed:18374639). Essential for osteoclastic bone resorption (PubMed:14739300). The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function (PubMed:14739300). May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBLB, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity).

Cellular Location


Cytoplasm. Cell membrane. Cell projection, cilium. Golgi apparatus. Note=Colocalizes with FGFR2 in lipid rafts at the cell membrane

Phospho-C-Cbl-Y770 Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Phospho-C-Cbl-Y770 Antibody - Images



Western blot analysis of extracts from HT29 cells untreated or treated with UV using c-Cbl (phospho-Tyr700) Antibody (Cat. #AE1007b).



Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Phospho-C-Cbl-Y770 Antibody (#AE1007b).



Immunofluorescence staining of methanol-fixed HeLa cells using Phospho-C-Cbl-Y770 Antibody

(#AE1007b, Red).

Phospho-C-Cbl-Y770 Antibody - Background

The cbl oncogene was first identified as part of a transforming retrovirus which induces mouse pre-B and pro-B cell lymphomas. As an adaptor protein for receptor protein-tyrosine kinases, it positively regulates receptor protein-tyrosine kinase ubiquitination in a manner dependent upon its variant SH2 and RING finger domains. Ubiquitination of receptor protein-tyrosine kinases terminates signaling by marking active receptors for degradation.

Phospho-C-Cbl-Y770 Antibody - References

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Niemeyer CM, et al. Nat Genet, 2010 Sep. PMID 20694012.
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. Rocquain J, et al. BMC Cancer, 2010 Aug 2. PMID 20678218.
Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Martinelli S, et al. Am J Hum Genet, 2010 Aug 13. PMID 20619386.
Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations. Matsuda K, et al. Blood, 2010 Jul 1. PMID 20595524.
c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells. Ye S, et al. J Biol Chem, 2010 Aug 27. PMID 20525683.